These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2137621)

  • 21. The effect of danazol and the LHRH agonist analogue goserelin (Zoladex) on the biological activity of luteinizing hormone in women with endometriosis.
    Maouris P; Dowsett M; Rose G; Edmonds DK; Rothwell C; Robertson WR
    Clin Endocrinol (Oxf); 1990 Oct; 33(4):539-46. PubMed ID: 2146047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical efficacy of long-term treatment with LH-RH analogue, ICI 118630 (Zoladex), in prostatic cancer patients. The Zoladex Multicenter Study Group].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Nihsijima T; Aso Y; Araki T; Itatani H
    Hinyokika Kiyo; 1988 Nov; 34(11):2059-66. PubMed ID: 2977261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group.
    Rock JA; Truglia JA; Caplan RJ
    Obstet Gynecol; 1993 Aug; 82(2):198-205. PubMed ID: 8336864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multi-centre randomised study to compare the effects of ovarian ablation with Zoladex depot in pre- and perimenopausal patients with advanced breast cancer.
    Tyrrell C
    Horm Res; 1989; 32 Suppl 1():218-20. PubMed ID: 2533154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zoladex (goserelin) in the treatment of benign gynaecological disorders: an overview of safety and efficacy.
    Miller RM; Frank RA
    Br J Obstet Gynaecol; 1992 Feb; 99 Suppl 7():37-41. PubMed ID: 1532509
    [No Abstract]   [Full Text] [Related]  

  • 26. A comparison between surgical orchidectomy and the LHRH agonist 'Zoladex' (ICI 188630) in the treatment of metastatic cancer of the prostate.
    Peeling WB
    Prog Clin Biol Res; 1989; 303():41-5. PubMed ID: 2528738
    [No Abstract]   [Full Text] [Related]  

  • 27. Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis--comparison of two dose regimens.
    Shaw RW; Matta W
    Clin Reprod Fertil; 1986 Oct; 4(5):329-36. PubMed ID: 3100012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of advanced prostatic carcinoma with a depot LH-RH analog (ICI 118630)].
    Grifoni R; Pierangeli T
    Minerva Urol Nefrol; 1989; 41(1):5-10. PubMed ID: 2527415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
    Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zoladex treatment of symptomatic prostatic carcinoma.
    Holdaway IM; Ibbertson HK; Croxson MS; Harvey V; Boulton J; Knox BS
    Am J Clin Oncol; 1988; 11 Suppl 2():S123-6. PubMed ID: 2977267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group Study.
    Emtage LA; Trethowan C; Kelly K; Arkell D; Wallace DM; Hughes M; Hay A; Blacklock R; Jones M; Rouse A
    Prog Clin Biol Res; 1989; 303():47-52. PubMed ID: 2528739
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical study on finding optimal dose of a potent LHRH agonist (buserelin) for the treatment of endometriosis--multicenter trial in Japan.
    Minaguchi H; Uemura T; Shirasu K
    Prog Clin Biol Res; 1986; 225():211-25. PubMed ID: 3097667
    [No Abstract]   [Full Text] [Related]  

  • 33. [Zoladex in prostatic carcinoma].
    Di Silverio F; Serio M
    Drugs Exp Clin Res; 1990; 16 Suppl():19-29. PubMed ID: 2150501
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
    Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B
    Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
    Peeling WB
    Urology; 1989 May; 33(5 Suppl):45-52. PubMed ID: 2523611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary treatment of advanced cancer of the prostate with Zoladex.
    Klarskov P; Lund F; Petersen SE
    Int Urol Nephrol; 1990; 22(4):359-62. PubMed ID: 2146234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocrinology of Zoladex in postmenopausal women.
    Dowsett M; Cantwell BM; Harris AL
    Horm Res; 1989; 32 Suppl 1():209-12. PubMed ID: 2533152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biodegradable sustained release formulation of the LH-RH analogue 'Zoladex' for the treatment of hormone-responsive tumours.
    Furr BJ; Hutchinson FG
    Prog Clin Biol Res; 1985; 185A():143-53. PubMed ID: 3162174
    [No Abstract]   [Full Text] [Related]  

  • 39. [Endocrine therapy of prostatic carcinoma with slow release (depot) formulation of the LH-RH analog ICI 118630 (Zoladex)].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Isurugi K; Niijima T; Aso Y; Araki T
    Hinyokika Kiyo; 1988 Feb; 34(2):369-82. PubMed ID: 2967622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of cancer of the prostate with Zoladex Depot].
    Bouffioux C; Focan C; Désirotte J; Andrianne R; de Leval J; Doupagne M; Franchimont P
    Rev Med Liege; 1986 May; 41(10):438-45. PubMed ID: 2943011
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.